English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, August 17, 2020
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China
Wednesday, July 1, 2020
华领医药宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨床研究24週核心研究取得正面結果
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin
Thursday, June 18, 2020
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial
华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究(HMM0301)
華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究(HMM0301)
Monday, April 27, 2020
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575